Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Mankind Pharma Ltd.
Change Company   
BSE Code 543904
ISIN Demat INE634S01028
Book Value 363.64
NSE Code MANKIND
Dividend Yield % 0.00
Market Cap 1062027.59
P/E 58.54
EPS 43.95
Face Value 1  
08-Sep-2025 Mankind rises on getting CDSCO’s approval for Pha...
20-Aug-2025 Mankind Pharma inches up on incorporating wholly ...
19-Aug-2025 Mankind Pharma incorporates wholly owned subsidia...
01-Aug-2025 Mankind Pharma reports 18% fall in Q1 consolidate...
01-Aug-2025 Mankind Pharma trades in green despite reporting ...
31-Jul-2025 Substantial Acquisition of Shares
10-Jun-2025 Mankind Pharma informs about allotment of equity ...
05-Jun-2025 Mankind Pharma gets ESG score of 38.98 from ISS E...
05-Jun-2025 Mankind Pharma gains on the BSE
22-May-2025 Mankind Pharma gets nod to incorporate wholly own...
22-May-2025 Mankind Pharma reports 11% fall in Q4 consolidate...
12-May-2025 Mankind Pharma informs about conference call
15-Apr-2025 Mankind Pharma gets nod to incorporate wholly own...
03-Apr-2025 Mankind Pharma informs about compliances certific...
01-Mar-2025 Mankind Pharma informs about disclosure
Page 1 of 2
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.